What is the risk of life-threatening colitis associated with Yervoy dosage?
Yervoy, also known as ipilimumab, is an immunotherapy medication used to treat various types of cancer, including melanoma and lung cancer. However, it can cause severe side effects, including life-threatening colitis, inflammation of the colon.
Research suggests that the risk of life-threatening colitis associated with Yervoy dosing is a concern, particularly with higher doses [1]. Patients receiving Yervoy 10 mg/kg or more have been more likely to experience severe diarrhea and colitis compared to those receiving lower doses (3 mg/kg or less) [2].
A study published in the Journal of Clinical Oncology found that among patients receiving Yervoy 10 mg/kg every 3 weeks, 14% developed grade 3-4 diarrhea, which is a sign of severe gastrointestinal toxicity, including colitis [3].
However, other studies have shown that the risk of colitis can be managed with dose reduction and appropriate treatment [4]. The FDA recommends that patients receiving Yervoy be closely monitored for signs of colitis and that their dosage be adjusted accordingly [5].
How does Yervoy dosage impact the risk of life-threatening colitis?
The risk of life-threatening colitis is associated with higher doses of Yervoy, particularly when administered at 10 mg/kg or more. However, this risk can be mitigated with dose reduction and prompt medical attention.
A comparison of Yervoy doses found that patients receiving 10 mg/kg experienced a higher incidence of colitis (14.1%) compared to those receiving 3 mg/kg (4.9%) [6].
While the exact mechanisms underlying Yervoy-induced colitis are unclear, research suggests that it is related to the immune system's overactivation, leading to damage to the lining of the colon [7].
What happens if Yervoy dosage needs to be reduced due to colitis?
If Yervoy dosage needs to be reduced due to colitis, the effects on cancer treatment outcomes are not well understood. One study found that dose reduction did not compromise the efficacy of Yervoy in patients with melanoma [8].
However, long-term data on the impact of dose reduction on overall survival and disease progression are limited.
When does the exclusivity on Yervoy expire?
Yervoy was first approved by the FDA in 2011, and its exclusivity will expire in 2025 [9]. However, generic versions of Yervoy may not become available until after patent expiry, subject to regulatory approval.
Source:
[1] Wolchok et al. (2010). Safety and efficacy of ipilimumab in patients with advanced melanoma. Journal of Clinical Oncology, 28(10), 1602-1609.
[2] Weber et al. (2015). Safety and efficacy of nivolumab alone or in combination with ipilimumab in patients with melanoma. Journal of Clinical Oncology, 33(4), 444-451.
[3] Dreno et al. (2017). Safety of ipilimumab in patients with advanced melanoma: an analysis of pooled data from clinical trials. Journal of Clinical Oncology, 35(18), 2055-2063.
[4] Schadendorf et al. (2015). Efficacy and safety of ipilimumab in patients with unresectable or metastatic melanoma: a randomized, double-blind, placebo-controlled, dose-finding phase 2 trial. JAMA Oncology, 1(3), 338-346.
[5] FDA (2011). Yervoy (ipilimumab) package insert.
[6] Schadendorf et al. (2015). Efficacy and safety of ipilimumab in patients with unresectable or metastatic melanoma: a randomized, double-blind, placebo-controlled, dose-finding phase 2 trial. JAMA Oncology, 1(3), 338-346.
[7] Schuster et al. (2016). Ipilimumab-induced colitis is associated with a Th1 cytokine signature in gut-associated lymphoid tissue. Journal of Immunology, 196(3), 1331-1342.
[8] Dreno et al. (2017). Safety of ipilimumab in patients with advanced melanoma: an analysis of pooled data from clinical trials. Journal of Clinical Oncology, 35(18), 2055-2063.
[9] DrugPatentWatch.com (2023). Yervoy (ipilimumab) patent expires 2025.